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ABSTRACT 18 
Weight gain is a major health problem among psychiatric populations. It implicates several receptors and 19 
hormones involved in energy balance and metabolism. Phosphoenolpyruvate carboxykinase 1 (PCK1) is 20 
a rate-controlling enzyme involved in gluconeogenesis, glyceroneogenesis and cataplerosis and has 21 
been related to obesity and diabetes phenotypes in animals and humans. The aim of this study was to 22 
investigate the association of PCK1 polymorphisms with metabolic traits in psychiatric patients treated 23 
with psychotropic drugs inducing weight gain and in general population samples. One polymorphism 24 
(rs11552145G>A) significantly associated with Body Mass Index in the psychiatric discovery sample 25 
(n=478) was replicated in 2 other psychiatric samples (n1=168, n2=188), with AA-genotype carriers having 26 
lower Body Mass Index as compared to G-allele carriers. Stronger associations were found among 27 
women younger than 45 years carrying AA-genotype as compared to G-allele carriers (-2.25 kg/m2, 28 
n=151, p=0.009) and in the discovery sample (-2.20 kg/m2, n=423, p=0.0004). In the discovery sample for 29 
which metabolic parameters were available, AA-genotype showed lower waist circumference (-6.86 cm, 30 
p=0.008) and triglycerides levels (-5.58 mg/100mL, p<0.002) when compared to G-allele carriers. Finally, 31 
waist to hip ratio was associated with rs6070157 (proxy of rs11552145, r2=0.99) in a population-based 32 
sample (N=123’865, p=0.022). Our results suggest an association of rs11552145G>A polymorphism with 33 
metabolic-related traits, especially in psychiatric populations and in women younger than 45 years old.   34 
5 
 
INTRODUCTION 35 
Weight gain is a known side-effect of psychotropic drugs such as antipsychotics, mood stabilizers and 36 
antidepressants.1 Psychotropic-induced weight gain can lead to many metabolic complications (e.g. 37 
increase in triglycerides, cholesterol, waist circumference) and is related to comorbidities such as 38 
diabetes, hypertension and other cardiovascular diseases.2 Psychiatric populations have a 10 to 25 year 39 
reduction in life expectancy due to comorbidities and to the psychiatric illness itself, corresponding to a 2-40 
3 fold increased mortality rate when compared to healthy populations.3 Obesity is attributed to the 41 
psychiatric illness, to behavioral and environmental factors (i.e. diet, exercise, smoking), as well as 42 
genetic factors.4 Besides, an interaction between genetic factors and psychotropic drug inducing weight 43 
gain has been described implicating several receptors (e.g. serotonin and dopamine receptors) and 44 
hormones (e.g. leptin) involved in energy balance or metabolism pathways.5, 6 45 
The Phosphoenolpyruvate carboxykinase (PCK) gene codes for an enzyme involved in the 46 
gluconeogenesis7 and is found in two forms, PCK1 (cytosolic) and  PCK2 (mitochondrial). Both enzymes 47 
are expressed equally in the liver but their expression may vary depending on the tissue.7, 8 PCK 48 
catalyzes the conversion from oxalacetate into phosphoenolpyruvate (a rate-controlling step of 49 
gluconeogenesis) and is also involved in glyceroneogenesis and cataplerosis.7 Of note, PCK is a 50 
downstream gene of the CREB-regulated transcription coactivator 1 (CRTC1) which is implicated in 51 
hypothalamic control of food intake9, 10 and we recently found in general and psychiatric populations that 52 
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carriers of a variant allele of a CRTC1 polymorphism appear to be protected against weight gain 53 
especially in women younger than 45 years old.11 54 
Rodents who over-express PCK1 and PCK2 were obese, hyperglycemic and insulin resistant12, 13 55 
whereas mice that under-expressed PCK1 and PCK2 developed a lipodistrophy type of metabolic 56 
syndrome.14 This is in line with the positive correlation found between PCK1 mRNA expression levels and 57 
Body Mass Index (BMI), body fat percentage, triglycerides (TG) and cholesterol (CHOL) levels in 58 
subcutaneous adipose tissue of non-menopausal women.15 In humans, regions near PCK1 locus have 59 
been related to obesity or fat mass16, 17 and several positive associations have been reported between 60 
PCK1 polymorphisms and type 2 diabetes18-20 although these results could not always be replicated.21 61 
Other studies conducted in the general population showed no significant association between PCK1 62 
polymorphisms and BMI, waist circumference (WC) or physical activity.22 A case-control study in a 63 
diabetic versus non diabetic population also found that non diabetic homozygous for the minor allele of a 64 
PCK1 polymorphism (+4824T>C) had increased levels of high density lipoproteins (HDL) and lower TG 65 
levels when compared to wild type.23 Thus growing evidence supports that PCK contributes to obesity 66 
and metabolic syndrome in the general population but, to our knowledge, no studies have yet been 67 
conducted in psychiatric populations which are at high risk for developing obesity and metabolic 68 
syndrome. The aim of the present study was to analyze whether PCK1 polymorphisms were associated 69 
with BMI and other metabolic traits (i.e. WC, blood glucose levels (BGL), low density lipoprotein (LDL), 70 
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HDL, CHOL and TG in three independent psychiatric populations treated with drugs inducing weight gain 71 
and in 3 large general population cohorts. As a secondary aim, we wanted to explore how PCK1 and 72 
CRTC1 polymorphisms are associated with BMI in a combined analysis. 73 
MATERIALS AND METHODS 74 
Psychiatric sample description 75 
The first psychiatric sample (discovery sample) was recruited during a longitudinal follow-up study on 76 
metabolic syndrome at the Lausanne Psychiatric University Hospital (started in 2007, ongoing). 478 77 
Caucasian patients switching or starting a treatment with drugs known to potentially induce weight gain 78 
(aripiprazole, amisulpride, clozapine, olanzapine, quetiapine, risperidone, mirtazapine, lithium and/or 79 
valproate) were included. Weight, height and other clinical variables were reported at baseline and at 1, 2, 80 
3, 6, 9 and 12 months after starting the treatment according to published monitoring guidelines of weight 81 
and metabolic syndrome parameters.24 Most patients had already received other psychotropic treatment 82 
before the current treatment. Fasting BGL and lipid levels (i.e. CHOL, TG, LDL, HDL) were analyzed on a 83 
routine basis on blood samples using a Modular P apparatus (Roche Diagnostics, Switzerland). For 84 
patients for whom drug plasma determinations were available, we conducted preliminary analysis on the 85 
influence of compliance on the observed associations. For this purpose, we defined an arbitrary threshold 86 
at 10% of the minimal therapeutic drug plasma concentration25 (i.e. 2, 35, 10, 2, 15, 10, 2 ng/mL, 0.05 87 
mmol/L, 5 mg/L for olanzapine, clozapine, quetiapine, risperidone + hydroxy-risperidone, aripiprazole, 88 
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amisulpride, paliperidone, lithium, and valproate) to ensure psychotropic drug intake. Similar results to 89 
those described in the present paper were obtained (data not shown). Thus, to increase the power of 90 
the study, the whole cohort was used for statistical analysis. Two other psychiatric samples were used as 91 
replication samples. A retrospective study (replication sample 1) was conducted in an outpatient setting in 92 
Geneva University Hospital in 2007. 168 Caucasian patients treated for at least 3 months with 93 
olanzapine, clozapine, quetiapine, risperidone, lithium and/or valproate were recruited. Another 94 
retrospective outpatient study in Lausanne, replication sample 2 (started in 2010, ongoing) included 188 95 
Caucasian patients mostly treated for more than one year with aripiprazole, amisulpride, clozapine, 96 
olanzapine, quetiapine, risperidone, mirtazapine, lithium and/or valproate. For both replication samples, 97 
questionnaires were filled during one of the patient routine follow-ups and weight, height, WC and 98 
treatment duration were reported among other clinical variables. Weight before starting psychotropic 99 
treatment was self-reported or extracted from medical files. As shown previously,11 self-reported weight 100 
was found to be a reliable estimate of the measured weight extracted from medical files. 101 
In all samples, patients with previous treatments were included after having switched medication. The 102 
latest introduced psychotropic medication was considered as the main psychotropic treatment. Weight 103 
(patients with light clothes and without shoes) was measured in kilograms to the nearest kg. Height was 104 
measured using a height gauge to the nearest cm. WC was measured to the nearest cm. BMI for all 105 
individuals was obtained by dividing weight (in kg) by squared height (in m2).  106 
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Written informed consent was provided by all individuals or by their legal representatives and the studies 107 
were approved by the ethics committee of the corresponding centers. Further details of the 3 psychiatric 108 
cohorts have already been described elsewhere.11, 26 Of note, the present study refers to the same 3 109 
psychiatric populations than in our previous paper,11 but with a larger number of patients included in the 110 
discovery cohort and in the replication sample 2 (inclusions ongoing).  111 
Population-based samples  112 
Significant results were tested for replication in three population based samples: Participants in CoLaus 113 
(n=5’338) were recruited between June 2003 and May 2006 in the Lausanne area as described 114 
previously.27 The Genetic Investigation of Anthropometric Traits Consortium (GIANT) performed a meta-115 
analysis of genome-wide association study data with a discovery set of 123’865 individuals of European 116 
ancestry from 46 studies for height,28 BMI,4 and waist-to-hip ratio (WHR).29 Finally, the second set of 117 
association summary statistics for general populations (Global Lipids Genetics Consortium) was 118 
downloaded from “Genome Wide Associations Scans for Total Cholesterol, HDL-C, LDL-C and 119 
triglycerides” website30  and contains data related to lipid traits (n=100’184). Of note, CoLaus is part of 120 
both GIANT and Global Lipids Genetics Consortium. 121 
SNP selection and Genotyping 122 
10 
 
In a first step, the best replicated and studied PCK1 polymorphism in the literature (i.e. rs2071023) was 123 
manually genotyped using TaqMan allelic discrimination assay (ABI PRISM 7000 Sequence Detection 124 
System; Applied Biosystems, Rotkreuz, Switzerland, TaqMan SNP genotyping assays ID: C   2508731 1). 125 
Additionally, three SNPS which were available in the CardioMetaboChip were also considered for 126 
analysis (i.e. rs11552145, rs707555 and rs8123020). The CardioMetaboChip is a custom Illumina iSelect 127 
genotyping array designed to test DNA variation of 200’000 SNPs from regions identified by large scale 128 
meta-analyses of genome wide association studies (GWAS) for metabolic and cardiovascular traits. 129 
Quality control excluded samples from the analysis if gender was inconsistent with genetic data from X-130 
linked markers, genotype call rate <0.96, Gene Call (GC) score <0.15. GenomeStudio Data Analysis 131 
Software was used to export results generated by Illumina CardioMetaboChip. In total, four SNPs were 132 
considered for analyses with minor allele frequency (MAF) higher than 0.10 (Table S-1). All of them were 133 
in Hardy Weinberg Equilibrium (HWE) (Table S-2). Finally, looking at HapMap Genome Browser (release 134 
27, MAF>0.10, cutoff of r2 set at 0.8),31 we found that several PCK1 tagging SNPs were in linkage 135 
disequilibrium (LD) with our four selected SNPs (see details in Figure S-1). 136 
DNA was extracted from blood samples as described by the manufacturer’s protocol using Flexigene 137 
DNA kit and QIAamp DNA Blood Mini QIAcube Kit (Qiagen AG, Switzerland) for 834 Caucasian patients 138 
from the three psychiatric cohorts. Genotyping of the rs3746266A>G SNP from CRTC1 was performed 139 
using TaqMan allelic discrimination assay (ABI PRISM 7000 Sequence Detection System; Applied 140 
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Biosystems, Rotkreuz, Switzerland) and according to the manufacturers protocol as described 141 
elsewhere.11 Genotyping of the CoLaus subjects was performed using the Affymetrix GeneChip Human 142 
Mapping 500K array set as previously described.27  143 
Variables of the study 144 
The main outcome analyzed in the three psychiatric samples was the BMI [kg/m2] used as a continuous 145 
variable. Other outcomes studied were WC [cm], LDL, HDL, TG, CHOL and BGL [mg/100mL]. PCK1 146 
genotypes were grouped and analyzed in recessive (for rs11552145, rs707555 and rs8123020) and 147 
dominant (for rs2071023) models according to their association with BMI showed in preliminary analyses. 148 
Other covariates were extracted from medical files or during the interview and included demographic data 149 
(i.e. sex, age and ethnicity) as well as history of treatment (type of psychotropic drug and treatment 150 
duration). In order to preserve homogeneity of the samples, only patients treated up to 24 months were 151 
taken into account in combined (i.e discovery plus replication) psychiatric sample analyses.  152 
Statistical analysis 153 
Psychiatric Samples 154 
HWE was determined for each polymorphism by a chi-square test. Statistical analyses were done using 155 
STATA 12.1 (StataCorp, College Station TX, USA) and R version 2.11.1 software.32 P-values less than 156 
0.05 were considered as statistically significant and when necessary, Bonferroni correction for multiple 157 
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tests was applied. Eventually, differences in sample size might be due to missing genotypes and/or 158 
covariates. First, exploratory analyses were conducted to explore differences in BMI between genetic 159 
groups in the three psychiatric samples using Mann–Whitney U non parametric test. To fit a longitudinal 160 
model on the BMI trend, due to complex and non-linear BMI evolution in time and presence of multiple 161 
observations per individual which introduces interdependence among observations, a Generalized 162 
Additive Mixed Model (GAMM) was used to assess the association of genetic polymorphism with BMI 163 
adjusted by sex, age, treatment and treatment duration. This allowed a smooth trend for the response in 164 
time based on multiple observations for each patient (using a thin plate regression spline basis). A 165 
random effect at the subject level was also introduced to take the dependence structure of observed data 166 
into account.33 The GAMMs were fitted using the mgcv package of R (settings were fixed at package 167 
defaults). To be more conservative, the uncertainty of estimated parameters was assessed by 1’000 168 
bootstraps on individuals. For those p-values lower than 0.001, 10’000 bootstraps were performed 169 
whenever possible. Multivariate analysis used the same methodology as previously described for the 170 
upstream CRTC1 gene:11 It was first conducted in the discovery sample and the significant results were 171 
tested for replication in the two replication samples. In fitted longitudinal models, stratification by sex, and 172 
in some cases by age, was applied when analyzing all samples together. Also, analyzes on WC and on 173 
other metabolic traits (i.e. BGL and lipid levels) were conducted in the discovery sample (data available 174 
only in this sample) and only for rs11552145 and rs2071023 polymorphisms. Due to some missing data 175 
and the relatively low number of variant alleles of rs707555 and rs8123020, analysis could not be 176 
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conducted for these polymorphisms. Finally it should be mentioned that preliminary analysis on PCK1 177 
haplotypes and BMI for the 3 SNPs that formed a haplotype block (i.e. rs11552145, rs707555 and 178 
rs8123020) showed no significant results (results not shown). 179 
Population-Based Samples 180 
Significant results from PCK1 polymorphisms in the discovery sample (i.e. rs6070157, proxy of 181 
rs11552145; r2=0.99 and rs2071023) were further tested for replication in the three population samples 182 
(CoLaus, GIANT and Global Lipids Genetics Consortium). 183 
The associations of PCK1 polymorphisms with adiposity markers such as BMI, WC, fat mass and lipid 184 
factors were analyzed using multiple linear regression with additive model in which potential confounding 185 
factors such as age, sex, and smoking status were added as covariates in the CoLaus study. For 186 
anthropometric traits (BMI, WHR) we performed lookups from the summary statistics of the GIANT 187 
consortium. For lipid traits (i.e. TG, HDL, CHOL), we looked up association results from the Global Lipid 188 
Consortium.30  189 
RESULTS 190 
Table S-3 shows the characteristics of the three psychiatric samples. The discovery sample included 191 
patients with the shortest treatment duration (median of 6 months versus 27.4 and 36 months in the 192 
replication 1 and 2, respectively, p=0.0001), as well as the lowest BMI (current median BMI of 25 versus 193 
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28 and 27 kg/m2 for replication 1 and 2, respectively, p=0.0001) and the lowest prevalence of obesity 194 
(BMI≥30 kg/m2) (18% versus 40% and 27%, respectively, p<0.001). 195 
Association of PCK1 polymorphisms with BMI in psychiatric populations 196 
Table S-2 shows PCK1 genotype distribution among the three psychiatric samples. No significant 197 
associations were found between PCK1 polymorphisms and baseline BMI when exploratory analyses 198 
were conducted (Table S-4). However, a trend and a significant association was found between 199 
rs11552145 and rs2071023 and current BMI (BMI at the last follow-up assessment) in the discovery (p-200 
corrected 0.08 and 0.018, respectively) and in the combined sample (p-corrected 0.01 and 0.003, 201 
respectively). Figure 1 shows the association of PCK1 rs11552145 polymorphism with BMI. 202 
Multivariate analyses were first conducted in the discovery sample for the four SNPs (Table 1). Carriers of 203 
rs11552145-AA genotype had, on average, 2.20 lower BMI units when compared to carriers of G-allele 204 
(p= 0.0004). Similar results were found for rs2071023-CC genotype which had 1.27 lower BMI units when 205 
compared to G-allele carriers (p= 0.004). Significant results were replicated for rs11552145 and BMI 206 
when combining the 2 replication samples. AA carriers had 1.42 lower BMI units when compared to G-207 
allele carriers (p= 0.009). When combining the three samples similar results were found for both 208 
rs11552145 and rs2071023 (estimates -1.89 and -1.11 kg/m2 and p<0.001 and p<0.001, respectively). 209 
Explained variances in the combined sample for rs11552145 and rs2071023 were 0.65% and 0.85%, 210 
respectively. For both rs11552145 and rs2071023, further analyses stratified by sex and age were 211 
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conducted in the three samples combined. rs2071023 was associated with BMI only in women whereas 212 
for rs11552145 an association was found in both genders, but a  stronger association was found among 213 
women younger than 45 years, where rs11552145 AA-carriers had 2.25 lower BMI units when compared 214 
to G-allele carriers (p-value 0.009, explained variance 0.77%). No significant results were found for the 215 
other two SNPs rs8123020 and rs707555. 216 
PCK1 polymorphisms and metabolic parameters in psychiatric populations 217 
The association of rs11552145 and rs2071023 with other metabolic parameters (i.e. WC, BGL, CHOL, 218 
HDL, LDL and TG) was analyzed in the discovery sample (Table 2). In agreement with results on BMI, 219 
both carriers of rs11552145-AA genotype and rs2071023-CC genotype had significantly lower WC (-6.86 220 
and -3.45 cm, p-values 0.008 and 0.004, respectively). In addition, rs11552145-AA genotype carriers had 221 
lower TG levels when compared to G-allele carriers (-27.59 mg/100mL, p-value <0.002). 222 
Association of CRTC1 and PCK1 with BMI 223 
Since PCK1 is a downstream gene of CRTC1, we wanted to further analyze the association of both 224 
CRTC1 rs3746266A>G previously associated with BMI11 and PCK1 rs11552145G>A with BMI over 225 
treatment duration (Figure 2). In the combined analysis, CRTC1 G-allele and PCK1 AA genotype were 226 
pooled together since carriers of these alleles showed lower BMI units when compared to others when 227 
analyzed individually. Thus, in the multivariate analysis adjusted by age, sex, treatment and treatment 228 
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duration (n=610), those carriers of AA genotype for CRTC1 and PCK1 or carriers of G-allele of CRTC1 229 
and PCK1 had 0.79 less units of BMI when compared to the reference group (p 0.009). Similarly, carriers 230 
of PCK1 AA genotype and CRTC1 G-allele had 2.43 less units of BMI compared to the reference group 231 
(p<0.001). 232 
Functional relevance of PCK1 polymorphisms 233 
We explored further the functional relevance of PCK1 polymorphisms. For rs11552145 and rs707555, the 234 
two variants in coding regions, PolyPhen-234 predicted both mutations to be benign. Further analysis on 235 
gene expression platform (GTEX portal35) showed significant differences in rs11552145 expression in 236 
subcutaneous adipose tissue with homozygous carriers of the variant allele having lower expression (p 237 
0.03). No differences were found for rs707555, rs8123020 or rs2071023. 238 
PCK1 polymorphisms in population-based samples 239 
The association of rs6070157 (proxy of rs11552145, r2=0.97) and rs2071023 with BMI and other 240 
metabolic features was further analyzed for replication in three population-based samples (GIANT, 241 
CoLaus and Global Lipids Genetics Consortium). Significant associations were found between the two 242 
PCK1 polymorphisms and the WHR in the GIANT cohort (N=123’865) for women and for both genders 243 
combined. In addition, significant associations were found for rs2071023 with HDL and TGL in the Global 244 
Lipids Genetics Consortium (N=100’184; p-values: 0.003 and 0.03, respectively) (Table 3).  245 
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DISCUSSION 246 
Growing evidence supports that PCK can contribute to obesity and metabolic syndrome both in animal 247 
models and in the general population.12-14, 16, 17 The main results from this study suggest that carriers of 248 
PCK1 rs11552145-AA genotype have lower BMI when compared to G-allele carriers in psychiatric 249 
patients treated with weight gain inducing drugs, this association being found in the discovery sample and 250 
in the replication samples analyzed together. Moreover, low WC and TG levels were associated with 251 
rs11552145-AA in the discovery sample and low BMI and WC were found as well for rs2071023-CC 252 
genotype. To our knowledge, this is the first study carried out in psychiatric patients and the first one to 253 
find a positive association between PCK1 polymorphisms and BMI. 254 
In addition, as a proof of concept, a positive association was found in the general population (GIANT 255 
cohort) with WHR and rs6070157 (proxy of rs11552145, r2=0.99) and rs2071023, again suggesting an 256 
association of  the polymorphisms with obesity traits, although the value was much weaker than in 257 
psychiatric samples and being of no clinical significance in the general population. This goes in the same 258 
line of what we found in previous results,11 since psychiatric populations are at high risk of obesity and/or 259 
metabolic syndrome. PCK1 function has been previously associated in animal models with glucose and 260 
lipid homeostasis and also with weight gain.36 In humans, the main investigated polymorphism is the -261 
232C/G (rs2071023) which is located in the promoter region of PCK1. This polymorphism has been 262 
previously associated with type 2 diabetes (T2DM) and gestational diabetes mellitus (GDM) but with 263 
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conflicting results in different ethnicities. Positive associations were found among South Asian and 264 
Japanese populations20, 37 concluding that carriers of the minor allele (GG) were at risk of developing 265 
T2DM, whereas no significant findings were found in German or Danish Caucasian populations.18, 21 266 
Finally, a case series study conducted in 3 Maltese women found that those who developed GDM carried 267 
the homozygous variant allele, but these results must be replicated in larger cohorts.38 In the present 268 
study, no association was found between rs2071023 and BGL, although the diabetes phenotype was not 269 
assessed. Additionally, and consistent with our results, another PCK1 polymorphism (rs707555) showed 270 
no significant association with anthropometric traits such as WC, weight and fat mass or BMI.22, 39  271 
Analyses were conducted in the combined discovery and replication samples for treatment duration up to 272 
24 months. Different effect sizes, detected in the discovery versus the replication samples, could be 273 
explained by lower prevalence of obesity at baseline and shorter treatment durations in the discovery 274 
sample (Table S-3), since both baseline BMI and treatment duration are moderators of weight gain.40 275 
However, to exclude a winner’s curse event, these results need to be replicated in other short treatment 276 
duration samples.  277 
Of note, in the present study as in previous genetic studies, genetically explained variances of BMI are 278 
quite low suggesting that BMI and metabolic features are influenced by multiple genetic factors as 279 
previously described in the literature.4 However, in the present study, rs11552145 was strongly 280 
associated with BMI in the subgroup of women younger than 45 years and the observed difference in BMI 281 
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between genotypes is of clinical significance. This result is in agreement with our previous study showing 282 
that the association between  a polymorphism of CRTC1 (an upstream gene of PCK1) and BMI was 283 
higher in women younger than 45 years as compared to non-gender stratified sample.11 In addition, a 284 
positive correlation was found between PCK1 mRNA expression levels and BMI in a study conducted 285 
with non-menopausal women.15 Other pharmacogenetic studies also highlighted the importance of 286 
stratifying by sex.41, 42 This finding could be tentatively explained by the influence of estrogen circulating 287 
levels on energy balance.43 Thus, a lack of estrogen in mice was related to obesity, decreasing fasting 288 
blood glucose levels, activating AMPK and reducing the expression of gluconeogenic genes, such as 289 
PCK in the liver.44, 45 However, this hypothesis could not be tested in our samples as estrogen circulating 290 
levels were not measured.   291 
In order to assess the contribution of PCK1 and CRTC1 polymorphisms on BMI, analyses combining both 292 
SNPs were conducted. An additive association with BMI was observed over treatment duration among 293 
carriers of CRTC1 rs3746266 G-allele and PCK1 rs11552145 AA genotype which had lower BMI when 294 
compared to the reference group. As described elsewhere,46 PCK family genes contain in their promoter 295 
region a CREB-regulated element binding site where CRTC1 binds, enhancing PCK expression. In the 296 
present study, the strongest associations were found among psychiatric population under psychotropic 297 
treatment which could be explained by the additive effect between PCK1 and CRTC1 genes and 298 
psychotropic drugs. In particular, CRTC1 is modulated, among other mechanisms, by adenosine 299 
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monophosphate protein kinase (AMPK) which is increased by antipsychotics.47 Besides, several 300 
polymorphisms on the AMPK gene, showed an association with weight gain induced by antipsychotics.48 301 
AMPK has also been related to gluconeogenesis modulation.49 Another study conducted in rats showed 302 
that olanzapine increased the mRNA levels of glucose-6-phosphatase in the liver.
47
 Although little is 303 
known about PCK family genes and psychotropic drugs, PCK expression is inhibited by lithium in isolated 304 
hepatocytes from fasted rats 50. In addition, chronic clozapine administration upregulates PCK expression 305 
in rat liver.51 Therefore, several genes coding for enzymes implicated in the gluconeogenic pathway have 306 
been associated with antipsychotics. 307 
Finally, in our sample, higher associations were found among psychiatric patients rather than in general 308 
population possibly explained by the high prevalence of overweight or obesity in psychiatric patients 309 
induced by the illness, the lifestyle (diet, physical activity), in addition to the direct effect of drug inducing 310 
weight gain. 311 
Some limitations of the present study must be mentioned. Firstly, patients were not drug naive, therefore, 312 
we could not assess whether the association between the polymorphisms and BMI or other phenotypes 313 
was influenced by the psychiatric illness itself and/or by the psychotropic treatment. Secondly, although 314 
the main inclusion criteria for patients in the present study was that they were receiving psychotropic 315 
drugs known to induce weight gain (i.e aripiprazole, amisulpride, clozapine, olanzapine, quetiapine, 316 
risperidone, mirtazapine, lithium and/or valproate), other drugs possibly inducing weight (psychotropic 317 
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and/or somatic drugs) were prescribed, the influence of which could not be evaluated. This study was 318 
conducted in Caucasians, thus results cannot be extrapolated to other ethnicities. Not all tagging SNPs 319 
could be tested due to limited availability of the genotypes. In addition, no significant associations with 320 
BMI were found for the two other tested SNPs (rs707555 and rs8123020), either because of a lack of 321 
effect or a lack of power due to the low MAF. Further replications of this study should increase sample 322 
size in order to test low MAF polymorphisms and to increase the coverage of PCK1 gene by including 323 
other tagging SNPs. Finally, variants obtained through GWAS should be also considered in further 324 
analysis, in particular those on gluconeogenic pathway. It has thus been recently shown that PCK1 325 
expression is regulated by CAMK1D,52 a gene previously related to diabetes in GWAS.53  326 
In conclusion, this is the first study investigating the association of PCK1 polymorphisms with BMI and 327 
other metabolic traits in psychiatric populations. Higher associations were found in psychiatric patients 328 
treated with psychotropic drugs over short periods, and in women younger than 45 years. In addition, the 329 
present study supports research on pathway related genes such as CRTC1 and PCK1, which may have 330 
an additive association with BMI. Further studies on the same and other pathways are therefore 331 
warranted, to increase our knowledge on the multiple genetic risk factors influencing obesity, lipid 332 
disturbances or metabolic syndrome in psychiatric population. This could ultimately help, by the 333 
determination and the combination of multiple genetic and clinical risk factors, to better adapt 334 
pharmacological treatments among particular populations at risk.  335 
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Table 1. Multivariate analysis of PCK1 polymorphisms and BMI. 
  
rs11552145  rs2071023  rs707555  rs8123020 
 
n 
BMI difference 
[kg/m
2
] between  
AA and G-allele 
carriers (95% CI) 
p-value 
E var 
(%) 
 
BMI difference 
[kg/m
2
] between  
CC and G-allele 
carriers (95% CI) 
p-value 
E var 
(%) 
 BMI difference 
[kg/m
2
] 
between GG and 
C-allele carriers 
(95% CI) 
p-value 
E var 
(%) 
 BMI difference 
[kg/m
2
] 
between TT and 
C-allele carriers  
(95% CI) 
p-value 
E var 
(%) 
Discovery 
Sample# 
423 -2.20 (-3.35 – (-)1.12) 0.0004
$
 0.84 
 
-1.27 (-2.09 – (-)0.49) 0.004
$
 1.24 
 
-0.38 (-3.26 – 2.21) 1.00
$
  
 
-0.83 (-2.46 – 0.82) 0.5
$
  
Replication 1 168 -1.82 (-4.24 – 0.45) 0.07  
 -0.73 (-1.97 – 0.61) 0.1          
Replication 2 183 -0.64 (-2.72 – 1.22) 0.2  
 -0.18 (-1.40 –  1.04) 0.4          
Replication 1 and 
Replication 2* 
337 -1.42 (-2.69 – (-)0.25) 0.009 0.49 
 
-0.53 (-1.40 –  0.41) 0.1  
 
   
 
   
Combined 
sample* 
760 -1.89 (-2.67 – (-)1.09) <0.001 0.65 
 
-1.11 (-1.71 – (-)0.52) <0.001 0.85 
 
   
 
   
Combined 
sample men* 
377 -1.98 (-3.18 – (-)0.85) 0.001 1.01 
 
-0.63 (-1.49 –  0.23) 0.08  
 
   
 
   
Combined 
sample women* 
383 -1.70 (-2.79 – (-)0.62) 0.002 0.35 
 
-1.58 (-2.41– (-)0.72) 0.0001 1.55 
 
   
 
   
Combined 
sample women 
<45 years* 
151 -2.25 (-4.18 – (-)0.45) 0.009 0.77 
 
-1.48 (-2.74 – (-)0.11) 0.01 0.57 
 
   
 
   
Combined 
sample women ≥ 
45 years* 
235 -1.54 (-3.59 – 0.86) 0.06 
 
 
-1.68 (-2.74 – (-)0.60) 0.002 1.63 
 
   
 
   
     
            
#bootstrap at 10 000. Only significant results in discovery sample were further tested for replication. 
$
p-corrected value for discovery sample. 
*Patients treated for up to 24 months. 
E var (%): explained variance by the polymorphism, only calculated for significant tests. 
Adjusted by: age, sex, treatment (antipsychotic or mood stabilizer) and treatment duration. Bootstrap at 1000. 
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Table 2. Association of PCK1 polymorphisms with other metabolic phenotypes in the 
discovery sample. 
 
rs11552145 n 
Difference between AA and 
G-allele carriers (95% CI) 
p-value$ E.var (%) 
WC [cm] 408 -6.86 (-11.07 – (-)2.59) 0.008 1.04 
HDL** [mg /100 mL] 305 5.85 (-1.95 – 14.04) 0.13 
 TG** [mg /100 mL] 305 -27.59 (-39.16 – (-)14.24) <0.002 0.90 
LDL** [mg /100 mL] 299 -10.14 (-19.89 – 2.34) 0.12 
 CHOL** [mg /100 mL] 307 -10.53 (-28.08 – 8.19) 0.28 
 BGL** [mg /100 mL] 289 -3.6 (-8.28 – 0.36) 0.09 
 
rs2071023 n 
Difference between CC and 
G-allele carriers (95% CI) 
p-value$ E.var (%) 
WC [cm] 409 -3.45 (-5.74 – (-)1.18) 0.004 1.14 
HDL** [mg /100 mL] 305 1.95 (-0.39 -  4.29) 0.12 
 TG** [mg /100 mL] 305 -8.01 (-19.58 – 3.56)  0.64 
 LDL** [mg /100 mL] 299 -2.34 (-10.14 – 5.07) 0.54 
 CHOL** [mg /100 mL] 307 -3.12 (-11.7 – 5.07) 0.32 
 BGL** [mg /100 mL] 289 2.52( -2.16 - 5.94) 0.42 
 **Fasting patients 
$
p-corrected value for discovery sample. 
E. var (%): explained variance by the polymorphism (%) calculated only for significant tests. 
Adjusted by: BMI, age, sex, treatment (antipsychotic or mood stabilizer) and treatment duration. Bootstrap at 1000. WC: waist 
circumference, HDL: high lipoprotein, TG: triglycerides, CHOL: cholesterol, BGL: blood glucose levels  
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Table 3. Association of PCK1 polymorphisms with metabolic traits in population based 
samples.   
 
 
 
 
CoLaus 
( n=5’338) 
 
GIANT 
(n= 123’865) 
 
Global Lipids Genetics 
Consortium (n= 100’184) 
rs6070157 
(proxy of  rs11552145, r2= 0.99) 
 β (SE) p-value  β (SE) p-value  β (SE) p-value 
Anthropometric traits  
  
 
 
    
BMI [kg/m2]  -0.0016 (0.0258) 0.95  0.0025 (0.0053) 0.63  N.A N.A 
WC [cm]  -0.0026 (0.0258) 0.92  N.A N.A  N.A N.A 
WHR  -0.0123 (0.0258) 0.63  -0.0163 (0.0071) 0.02  N.A N.A 
Men  0.0086 (0.038) 0.82   0.0151 (0.0096) 0.11  N.A N.A 
Women  -0.0308 (0.035) 0.39  -0.0202 (0.0089) 0.02  N.A N.A 
Lipids  
  
 
 
    
HDL [mg /100 mL]  0.38 (0.37) 0.30  N.A N.A  0.16 (0.12) 0.20 
CHOL [mg /100 mL]  -0.14 (1.02) 0.89  N.A N.A  0.05 (0.12) 0.69 
TG [mg /100 mL]  -3.25 (2.57) 0.21  N.A N.A  -0.10 (-0.28) 0.73 
LDL [mg /100 mL]  -0. 41 (0.90) 0.65  N.A N.A  N.A N.A 
BGL [mg /100 mL]  0.85 (0.55) 0.12  N.A N.A  -0.06 (-0.08) 0.50 
rs2071023  β (SE) p-value  β (SE) p-value  β (SE) p-value 
Anthropometric traits  
  
 
 
    
BMI [kg/m2]  -0.0196 (0.0198) 0.32  -0.0028 (0.0043) 0.2  N.A N.A 
WC [cm]  -0.0087 (0.0198) 0.66  N.A N.A  N.A N.A 
WHR  0.0026 (0.0198) 0.90  -0.0195 (0.0057) 0.001  N.A N.A 
Men  -0.0145 (0.029) 0.61  -0.0013 (0.0077) 0.87  N.A N.A 
Women  0.0184 (0.028) 0.50  -0.0154 (0.0071) 0.03  N.A N.A 
Lipids  
  
 
 
    
HDL [mg /100 mL]  -0.54 (0.28) 0.06  N.A N.A  0.28 (0.12) 0.003 
CHOL [mg /100 mL]  -0.99 (0.78) 0.20  N.A N.A  0.078 (0.12) 0.54 
TG [mg /100 mL]  1.11 (1.98) 0.57  N.A N.A  -0.61 (-0.28) 0.03 
LDL [mg /100 mL]  -0.58 (0.69) 0.41  N.A N.A  N.A N.A 
BGL [mg /100 mL]  -0.35 (0.42) 0.41  N.A N.A  -0.09 (-0.07) 0.16 
N.A: Data not available. BMI: Body Mass Index, WC: waist circumference, WHR: waist-to-hip ratio, HDL: high lipoprotein 
cholesterol, CHOL: cholesterol, TG: triglycerides, LDL: low lipoprotein cholesterol, BGL: blood glucose levels. 
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Figure 1. BMI in relation to rs11552145 G>A genotypes in the combined sample presented at different time periods 
of the current psychotropic treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Boxplots show median values of BMI for each time of the treatment duration (solid horizontal line), 25th 
and 75th percentile values (box outline), the lowest and upper value within 1.5 Interquartile range 
(whiskers) and outlier values (open circles). 
33 
 
Figure 2. Association of PCK1 rs11552145 and CRTC1 rs3746266 genotypes with BMI 
over the time in all samples. 
 
  
 
  
 
* Reference group.  
Boxplots show median values of BMI for each time of the treatment duration (solid horizontal line), 25th 
and 75th percentile values (box outline), the lowest and upper value within 1.5 Interquartile range 
(whiskers) and outlier values (open circles). 
      PCK1 G-allele + CRTC1 AA genotype* 
      PCK1 AA genotype + CRTC1 AA   genotype                     
or PCK1 G-allele + CRTC1 G-allele 
      PCK1 AA genotype + CRTC1 G-allele 
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Table S-1. Selected descriptions of polymorphisms and Minor Allele Frequencies (MAF). 
variant position in gene type of variation 
major / 
minor allele 
MAF in combined 
psychiatric sample 
MAF in 
Caucasians* 
rs11552145 chr 20:56138648 missense Glu>Lys G/A 0.17 0.16 
rs707555 chr 20:56137895 missense Leu>Val G/C 0.12 0.14 
rs8123020 chr 20:56137061 intron variant  C/T 0.12 0.12 
rs2071023 chr 20:56135934 5' near gene C/G 0.46 0.48 
*Source: 1000 Genomes project (http://www.ensembl.org/index.html)
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Table S-2. HWE and PCK1 genotypes distribution among three psychiatric cohorts. 
rs11552145 Discovery sample Replication 1 Replication 2 Combined Sample 
GG 478 141 173 792 
GA 197 49 72 318 
AA 30 8 11 49 
HWE (p
$
-value) 0.40 0.68 1.00 0.08 
rs707555 Discovery sample Replication 1 Replication 2 Combined Sample 
CC 547 166 190 903 
CG 142 29 61 232 
GG 16 3 6 25 
HWE (p
$
-value) 0.28 0.80 1.00 0.12 
rs8123020 Discovery sample Replication 1 Replication 2 Combined Sample 
CC 546 140 193 879 
CT 149 55 62 266 
TT 11 3 2 16 
HWE (p
$
-value) 1.00 1.00 0.84 1.00 
rs2071023 Discovery sample Replication 1 Replication 2 Combined Sample 
CC 217 52 69 338 
CG 333 103 122 558 
GG 153 41 53 247 
HWE (p
$
-value) 0.96 1.00 1.00 1.00 
$
p-corrected value 
  
36 
 
Table S-3. Description of demographic and clinical psychiatric Caucasian samples. 
Characteristics 
Discovery 
Sample 
n = 478 
Replication 
Sample 1 
n = 168 
Replication 
Sample 2 
n = 188 
Combined 
sample 
n= 834 
Male,% 44 53 62 50 
Age, median (range), years 50 (12-96) 42 (19-64) 42 (19-69) 45 (12-96) 
Diagnosis         
Psychotic disorders,% 33.3 27.5 43.4 34.5 
Schizo-affective disorders,% 6.5 15.6 12.1 10 
Bipolar disorders,% 19.9 32.9 17 22.2 
Depression disorders,% 20.4 16.8 13.7 17.9 
Others diagnosis,% 19.9 7.2 13.7 15.4 
Initial BMI status
 ‡
         
BMI, median (range), kg/m
2 
 24 (13-44) 25 (15-46) 25 (16-46) 24 (13-46) 
Overweight (25≥ Initial BMI<30), %
 
 23 36 32 28 
Obese (Initial BMI≥ 30), %  14 15 15 14 
Current BMI status
 #
         
     BMI, median (range), kg/m
2
 25 (15-50) 28 (16-42) 27 (17-44) 25 (15-50) 
Overweight (25≥ Current BMI<30), % 26 30 34 27 
Obese (Current BMI≥ 30), % 18 40 27 24 
Initial waist circumference
‡
         
     WC, median (range), cm 90 (54-138) -- -- 87 (54-138) 
High WC ≥ 94cm (male), 88cm (female), %
 
 43 (n=315) -- -- 43 (n=315) 
Current waist circumference
 #
         
     WC, median (range), cm 93 (48 – 162) -- 98 (51-148) 95 (48-162) 
High WC ≥ 94 (male), 88 (female), %
 
 54 (n=592) -- 64 (n=182) 57 (n=774) 
Initial Lipid status
 ‡
         
   High LDL, % (n)
a 
9 (n=224) -- -- 9 (n=224) 
   High TG, % (n)
b 
19 (n=234) -- -- 19 (n=234) 
   Low HDL, % (n)
c 
25 (n=222) -- -- 25 (n=222) 
Current Lipid status
 #
         
   High LDL, % (n)
a 
14 (n=383) -- -- 15 (n=363) 
   High TG, % (n)
b 
28 (n=402) -- -- 28 (n=402) 
   Low HDL, % (n)
c 
27 (n=359) 28 (n=164) 19 (n=160) 26 (n=665) 
          
Smoker, % 41 60 75 50 
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Discovery 
Sample 
n = 478 
Replication 
Sample 1 
n = 168 
Replication 
Sample 2 
n = 188 
Combined 
sample 
n= 834 
Prescribed psychotropic drug        
Amisulpride, % 8 - 10 7 
Aripirazole, % 10 - 8 8 
Clozapine, % 8 14 9 9 
Olanzapine, % 10 16 12 11 
Quetiapine, % 31 18 23 28 
Risperidone, % 16 17 16 16 
Lithium, % 7 20 12 10 
Valproate, % 4 14 8 6 
Treatment duration, median (range), 
months 6 (1-12) 27.4 (3-333) 36 (1-390) 9 (1-390) 
   
‡ Before the current psychotropic treatment 
# For replication Sample 1, 2 : current observation ; for discovery cohort : last follow-up 
-- Missing clinical values or obtained in non fasting conditions  
a. High LDL cholesterol : equal or higher than 160 mg/100 mL 
b. High triglycerides : equal or higher than 196 mg/100 mL 
c. Low HDL cholesterol : lower than 39 mg/100 mL 
BMI: body mass index, WC: waist circumference, LDL: low density lipoprotein, TG: triglycerides,  HDL: 
high density lipoprotein 
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Table S-4. Exploratory analysis of the association of PCK1 polymorphisms with BMI in the three psychiatric samples. 
  Discovery Sample
#
  Replication 1  Replication 2  Combined Sample* 
B
a
se
lin
e 
B
M
I 
rs11552145 AA G-allele p-value
$
  AA G-allele p-value  AA G-allele p-value  AA G-allele p-value 
n 22 354 
0.36 
 8 131 
0.49 
 10 169 
0.46 
 40 654 
0.05 
BMI [kg/m
2
] (SE) 22.4 (0.7) 24.3 (0.3)  24.3 (1.4) 25.5 (0.4)  23.8 (0.7) 25 (0.4)  23.1 (0.5) 24.7 (0.2) 
rs707555 GG C-allele p-value
$
    
 
   
 
   
 n 10 366 
1.00 
         
BMI [kg/m
2
] (SE) 23.6 (6.7) 24.2 (5.1)          
rs8123020 TT C-allele p-value
$
             
n 10 366 
1.00 
   
 
   
 
   
 
BMI [kg/m
2
] (SE) 23.4 (3.1) 24.2 (5.2)          
rs2071023 CC G-allele p-value
$
  CC G-allele p-value  CC G-allele p-value  CC G-allele p-value 
n 122 277 
0.28 
 33 106 
0.66 
 46 130 
0.58 
 194 496 
0.048 
BMI [kg/m
2
] (SE) 23.6 (0.5) 24.4 (0.3)  24.8 (0.6) 25.6 (0.5)  24.5 (0.7) 25.0 (0.5)  24.0 (0.4) 24.8 (0.2) 
 Discovery Sample
#
  Replication 1  Replication 2  Combined Sample* 
C
u
rr
en
t 
B
M
I 
rs11552145 AA G-allele p-value
$
  AA G-allele p-value  AA G-allele p-value  AA G-allele p-value 
n 12 421 
0.08 
 8 160 
0.57 
 11 170 
0.80 
 30 742 
0.01 
BMI [kg/m
2
] (SE) 22.8 (2.9) 25.4 (5.4)  27.1 (1.3) 28.2 (0.4)  26.9 (1.6) 27.3 (0.4)  23.3 (0.6) 25.7 (0.2) 
rs707555 CC G-allele p-value
$
             
n 12 421 1.00 
 
   
 
   
 
    
BMI [kg/m
2
] (SE) 25.1 (6.1) 25.3 (5.4)          
rs8123020 TT C-allele p-value
$
             
n 10 423 
1.00 
   
 
   
 
    
BMI [kg/m
2
] (SE) 25.8 (2.6) 25.3 (5.4)          
rs2071023 CC G-allele p-value
$
  CC G-allele p-value  CC G-allele p-value  CC G-allele p-value 
n 143 333 
0.018 
 39 128 
0.41 
 49 132 
0.88 
 287 722 
0.003 
BMI [kg/m
2
] (SE) 24.5 (0.5) 25.7 (0.3)  27.5 (0.7) 28.3 (0.5)  26.9 (0.7) 27.3 (0.5)  25.3 (0.3) 26.4 (0.2) 
# For current BMI, only significant findings in the discovery sample were further tested for replication. The same SNPs were also tested for replication at the baseline BMI.  
*Only patients treated for up to 24 months. 
 
$
p-corrected value for the discovery sample. 
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Figure S-1: Pairwise linkage disequilibrium (LD) in CEU HapMap samples for PCK1 
polmorphisms. LD expressed as r2. 
* SNPs tested in the present study, including SNPs in LD with one of the four analyzed SNPs. rs2071023 (not present in the figure) 
is in LD with rs1062600 (r
2
=1), rs1062601 (r
2
=0.81) and rs1042523 (r
2
=0.82). rs11552145 is in LD with rs6070157 (r
2
=0.97). 
rs8123020 is in LD with rs8192708 (r
2
=0.94). 
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